Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 19/20 | 0.77 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA9 | Q16790 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 2/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5707697 | 1.00 | STS (0.77) | STSCA1CA2CA9ESR1 | |
| SCHEMBL5707476 | 0.92 | STS (0.78) | STSCA1CA2CA9ESR1 | |
| SCHEMBL5707482 | 0.92 | STS (0.78) | STSCA1CA2CA9ESR1 | |
| SCHEMBL5707458 | 0.90 | STS (0.85) | STSCA1CA2CA9ESR1 | |
| SCHEMBL5707460 | 0.90 | STS (0.85) | STSCA1CA2CA9ESR1 | |
| SCHEMBL5707488 | 0.89 | STS (0.81) | STSCA1CA2CA9ESR1 | |
| SCHEMBL5707485 | 0.89 | STS (0.81) | STSCA1CA2CA9ESR1 | |
| SCHEMBL14596903 | 0.87 | STS (1.00) | STSCA1CA2CA9ESR1 | |
| SCHEMBL5707498 | 0.87 | STS (1.00) | STSCA1CA2CA9ESR1 | |
| SCHEMBL5707499 | 0.87 | STS (1.00) | STSCA1CA2CA9ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1147124-B1 | STEROID SULFATASE INHIBITORS AND METHODS FOR MAKING AND USING THE SAME | UNIV HOLY GHOST DUQUESNE (US) | 2006-08-30 | — | — | EP | disclosed |
| US-6436918-B1 | SULFAMATE- AND AMINOCARBONYL- SUBSTITUTED STEROID RING SYSTEM HAVING 4 ATTACHED RINGS; THERAPEUTIC AND PROPHYLACTIC TREATMENTS FOR ESTROGEN DEPENDENT ILLNESSES. | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2002-08-20 | — | — | US | disclosed |
| US-20020068726-A1 | Steroid sulfatase inhibitors and methods for making and using the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2002-06-06 | — | — | US | disclosed |
| US-6376687-B1 | THERAPY FOR ESTROGEN SENSITIVE DISEASES | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2002-04-23 | — | — | US | disclosed |
| EP-1147124-A2 | STEROID SULFATASE INHIBITORS AND METHODS FOR MAKING AND USING THE SAME | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000043408-A2 | STEROID SULFATASE INHIBITORS AND METHODS FOR MAKING AND USING THE SAME | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068726-A1 | Steroid sulfatase inhibitors and methods for making and using the same | STS, HSD17B11, CYP21A2 | STS 1/4885CA1 361/4885CA2 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.